Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label dosing and safety study of crizanlizumab in pediatric sickle cell disease
2017-001747-12Phase 2Unknown
- Sponsor
- Novartis
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of crizanlizumab in sickle cell disease (SCD), sponsored by Novartis. Primary endpoint: PK (AUCd15) after 1st dose. Status: unknown.
02
Drugs
crizanlizumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2017-001747-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001747-12.